Ignite Creation Date:
2024-05-06 @ 2:23 PM
Last Modification Date:
2024-10-26 @ 1:30 PM
Study NCT ID:
NCT04309084
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-02-16
First Post:
2020-03-12
Brief Title:
Natural Killer Cell CYNK-001 Infusions in Adults With Multiple Myeloma
Sponsor:
Celularity Incorporated
Organization:
Celularity Incorporated
Study Overview
Official Title:
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells CYNK 001 in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will find the maximum tolerated dose MTD of CYNK-001 which contain NK cells derived from human placental CD34 cells and culture-expanded CYNK-001 cells will be given post Autologous Stem Cell Transplant ASCT The safety of this treatment will be evaluated and researchers will want to learn if NK cells will help in treating Multiple Myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None